In an increasingly tech-focused world, the use of phones, tablets, and computes, combined with social media sites, have allowed patients to find the emotional and social interactions they need when dealing with their care, said Mike Payne, MBA, MSci, chief healthcare development officer at Omada Health.
In an increasingly tech-focused world, the use of phones, tablets, and computes, combined with social media sites, have allowed patients to find the emotional and social interactions they need when dealing with their care, said Mike Payne, MBA, MSci, chief healthcare development officer at Omada Health.
Transcript (slightly modified)
What are some of the most prominent changes you’ve seen in diabetes care as a result of an increasingly tech-focused world?
—
—
I think technology is empowering patients, whether they’re pre-diabetic patients or diabetic patients, and it’s not just accessibility. It’s not just classic telehealth. It’s the ability through ubiquitous phones and tablets and computers and censors, as well as, frankly, the comfort of individuals, whether they’re pre-diabetic or diabetic, with having emotional, social interactions online. And in some ways, we as a healthcare communityI hate to say ithave Facebook to thank for that.
That dynamic has been driven by the social media scene and it’s very relevant for seniors. They interact with their grandchildren online and so for us, pre-diabetic and diabetic seniors is a big area of focus because the fallacy, and it is a fallacy, of seniors not being able to interact with their health through technology is a very important myth for us to dispel in the healthcare world.
Inside the Center's MDD Value Model and Its Use of Dynamic Pricing
May 13th 2025Larragem Raines, MS, of the Center for Innovation & Value Research, discusses the organization's major depressive disorder (MDD) open-source value model, dynamic pricing, and the future role of artificial intelligence in care.
Listen
Real-World Data Show Bevacizumab Benefits Only High-Risk Patients With Epithelial Ovarian Cancer
May 13th 2025In line with previous clinical trial findings, real-world data show that bevacizumab improves outcomes in patients with epithelial ovarian cancer and high-risk prognostic factors.
Read More
For Patients Who Cannot Wait, This Off-the-Shelf CAR NK Treatment for AML Leaves Healthy Cells Alone
May 12th 2025First part of a 2-part interview with Stephen Strickland, MD, MSCI, director of leukemia research for Sarah Cannon Research Institute. Strickland recently presented data from a phase 1 trial of SENTI-202, an investigational chimeric antigen receptor (CAR) natural killer (NK) cell therapy.
Read More